Google Cloud's updated its Vertex AI platform to support AI agents with including the Agent Development Kit, the Agent2Agent ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Vertex Growth, a subsidiary of Temasek, has invested €10 million in Dolphin Semiconductor, a provider of semiconductor IP solutions. Vertex joins existing investor Jolt Capital, which in 2024 acquired ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to release its first quarter 2025 financial results on Wednesday, May 7, 2025 ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...